Integral Derivatives’s Teva Pharmaceuticals TEVA Stock Holding History

Integral Derivatives’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-32,601	Closed	-$1.01M	–	1267
2017 Q1	$1.05M	Sell	32,601 -37,565	-54%	-$1.28M	0.02%	509
2016 Q4	$2.54M	Buy	70,166 +37,601	+115%	+$1.5M	0.05%	259
2016 Q3	$1.5M	Buy	32,565 +11,804	+57%	+$616K	0.03%	338
2016 Q2	$1.04M	Buy	20,761 +7,500	+57%	+$399K	0.03%	408
2016 Q1	$710K	Buy	+13,261	New	+$778K	0.02%	438
2015 Q1	–	Sell	-23,289	Closed	-$1.35M	–	1370
2014 Q4	$1.34M	Buy	+23,289	New	+$1.3M	0.02%	575
2014 Q3	–	Sell	-28,539	Closed	-$1.51M	–	1532
2014 Q2	$1.5M	Buy	+28,539	New	+$1.46M	0.03%	531
2014 Q1	–	Sell	-49,830	Closed	-$2.3M	–	1573
2013 Q4	$2M	Buy	+49,830	New	+$1.96M	0.03%	495

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Integral Derivatives's TEVA Position: Q2 2017 in Review

Integral Derivatives sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 32,601 shares — an estimated $1.01M sold.

Integral Derivatives first reported a position in TEVA in Q4 2013 and held it in 8 quarters. The position peaked at $2.54M in Q4 2016. 649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Integral Derivatives reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Integral Derivatives sold 32,601 Teva Pharmaceuticals shares in Q2 2017, an estimated $1.01M.
Integral Derivatives first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Integral Derivatives's Teva Pharmaceuticals position peaked at $2.54M in Q4 2016.
649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.